Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of CX1440 capsules in adults with chronic urticaria
CTR20253179Phase 2Active
- Sponsor
- Hangzhou Bangshun Pharmaceutical
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of bangsaitinib in chronic urticaria (CU), chronic idiopathic urticaria (CIU), chronic inducible urticaria (CIndU), sponsored by Hangzhou Bangshun Pharmaceutical. Started Sep 2025; status: active.
02
Drugs
bangsaitinib
03
Conditions
chronic urticaria (CU)chronic idiopathic urticaria (CIU)chronic inducible urticaria (CIndU)
Beyond the preview
Go deeper on CTR20253179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253179.